AstraZeneca drug approved in US to reduce risk of heart failure in type-2 diabetes patients

07:31 21/10/2019
StockMarketWire.com - AstraZeneca said its type-2 diabetes drug was approved by US regulators to reduce the risk of hospitalisation for heart failure in adults with the condition and established cardiovascular disease.

The approval came on the back of results from a Declare-Timi 58 cardiovascular outcomes trial (CVOT), to evaluate type-2 diabetes patients with multiple cardiovascular risk factors or established cardiovascular disease.

'This is promising news for the 30m people living with type-2 diabetes in the US, as heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke,' said Ruud Dobber, executive vice president of the company's biopharmaceuticals business unit.

'Farxiga now offers the opportunity for physicians to act sooner and reduce the risk of hospitalisation for heart failure.'

Story provided by StockMarketWire.com

Forex

Commodities

What the Papers Say

telegraph financial times daily mail daily express independent times
11:30 House prices to rise by £35,000 on...
source: The Daily Mail
11:29 Unilever chairman steps down after U-turn...
source: The Daily Mail
11:28 Toshiba launches offers for three listed...
source: FT.com
11:24 Tencent profits fall as threat from...
source: FT.com
11:23 The £65,000 Range Rover Sport is the...
source: The Daily Mail
11:20 UK inflation hits three-year low; London...
source: The Guardian
11:19 Wary investors edge back into European...
source: FT.com
11:14 New Land Rover Defender revealed in No...
source: The Daily Mail
11:13 House prices to rise by £35,000 on...
source: The Daily Mail
11:02 FTSE LIVE: Wetherspoon boss hits out at...
source: The Daily Mail
[more ...]